Dr Jeanette Pritchard

Manager, Imaging Delivery & Sensing

Nanotechnology Victoria Ltd

Suite 201, Level 2, 3 Chester Street
Oakleigh
Victoria
3166
Australia

PH: +61 (3) 95673708
Fax: +61 (3) 95681214
Email: [email protected]
Click here to visit Web Site

Background

Dr Jeanette Pritchard joined Nanotechnology Victoria Ltd. in May 2006, as part of the Delivery and Sensing Team. Jeanettes primary focus has been to develop NanoVics Diagnostics portfolio, with particular emphasis on medical imaging for the in vivo detection of human diseases. During her time at NanoVic, Jeanette has been responsible for managing three Demonstration Projects and also for securing funds towards a $1.5 million imaging program, with the University of Melbourne and Baker Heart Research Institute. Jeanette has also been instrumental in the formation of Quintain NanoSystems, the vehicle established for commercialisation of NanoVics diagnostic imaging activities, with the focus being the development of nanoparticle-based targeted contrast agents. An integral part of establishing Quintain NS has been the production of the Business Plan, which was recently completed in close collaboration with Capstone Partners.

Prior to joining NanoVic, Jeanette held roles in two Biotechnology companies in the UK. As Senior Biosensor Scientist at Sphere Medical Ltd (Cambridge, England), she was responsible for developing the enzyme-based biosensor component of the companies Proxima medical detection system. During her time at Applied Enzyme Technology (Pontypool, Wales), Jeanettes role as Senior Project Leader involved commercialisation of biosensor devices, in addition to business development activities and laboratory/project management.

Major Qualifications

Jeanettes academic background was focused on electrochemical biosensor devices for medical and environmental applications. Her PhD, awarded in 2000, and subsequent post-doctoral role at the University of Newcastle upon Tyne entailed the development of lateral flow clinical devices for the quantitative measurement of cardiac marker proteins, such as myoglobin and fatty acid binding protein (FABP).